213 related articles for article (PubMed ID: 15667646)
1. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
Gosselaar C; Roobol MJ; Schröder FH
BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
[TBL] [Abstract][Full Text] [Related]
2. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
4. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
5. Do clinically insignificant tumors of the prostate exist?
Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of prostate cancers detected at low PSA levels.
Horninger W; Berger AP; Rogatsch H; Gschwendtner A; Steiner H; Niescher M; Klocker H; Bartsch G
Prostate; 2004 Feb; 58(3):232-7. PubMed ID: 14743461
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference?
Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Pallwein L; Mitterberger M; Steiner E; Bartsch G; Horninger W
BJU Int; 2008 Jul; 102(1):24-7. PubMed ID: 18341623
[TBL] [Abstract][Full Text] [Related]
8. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
9. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
Loeb S; Gonzalez CM; Roehl KA; Han M; Antenor JA; Yap RL; Catalona WJ
J Urol; 2006 Mar; 175(3 Pt 1):902-6. PubMed ID: 16469576
[TBL] [Abstract][Full Text] [Related]
10. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
11. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
Park HK; Hong SK; Byun SS; Lee SE
Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
[TBL] [Abstract][Full Text] [Related]
12. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
14. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
15. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
16. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
17. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
Porter MP; Stanford JL; Lange PH
Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
19. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
Van der Kwast TH; Postma R; Hoedemaeker RF; van Leenders GJ; Schröder FH
Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
[TBL] [Abstract][Full Text] [Related]
20. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
J Clin Oncol; 2005 Aug; 23(22):4975-9. PubMed ID: 16051949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
